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Systemic lupus erythematosus (SLE) is a clinically heterogeneous disease affecting multiple organ
systems and characterized by autoantibody formation to nuclear components. Although genetic
variation within the major histocompatibility complex (MHC) is associated with SLE, its role in
the development of clinical manifestations and autoantibody production is not well defined. We
conducted a meta-analysis of four independent European SLE case collections for associations
between SLE sub-phenotypes and MHC single-nucleotide polymorphism genotypes, human
leukocyte antigen (HLA) alleles and variant HLA amino acids. Of the 11 American College of
Rheumatology criteria and 7 autoantibody sub-phenotypes examined, anti-Ro/SSA and antiLa/SSB antibody subsets exhibited the highest number and most statistically significant
associations. HLA-DRB1*03:01 was significantly associated with both sub-phenotypes. We found
evidence of associations independent of MHC class II variants in the anti-Ro subset alone.
Conditional analyses showed that anti-Ro and anti-La subsets are independently associated with
HLA-DRB1*0301, and that the HLA-DRB1*03:01 association with SLE is largely but not
completely driven by the association of this allele with these sub-phenotypes. Our results provide
strong evidence for a multilevel risk model for HLA-DRB1*03:01 in SLE, where the association
with anti-Ro and anti-La antibody-positive SLE is much stronger than SLE without these
autoantibodies.
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INTRODUCTION
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Systemic lupus erythematosus (SLE; OMIM 152700) is a complex autoimmune disease that
can affect multiple organ systems. Processes involving both the innate and adaptive immune
systems contribute to its development.1 The disease is clinically heterogeneous, and affected
individuals only need 4 out of 11 of the American College of Rheumatology (ACR) criteria
to be classified as having SLE. Although patients may differ in their clinical manifestations,
patients do share a propensity to develop autoantibodies directed against nucleic acids and
associated nuclear and cellular proteins.
There is overwhelming evidence of a genetic component to SLE risk with higher
concordance rates observed between monozygotic twins (20–40%) compared with dizygotic
twins (2–5%).2 The familial aggregation for SLE (sibling risk ratio, λs = 8–29)2,3 is higher
than other autoimmune diseases, and the estimate of heritability is approximately 66%.4
Genes Immun. Author manuscript; available in PMC 2014 July 18.
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Genetic association studies of SLE have been successful in identifying multiple loci.5–11
However, relatively few studies have investigated the genetic association with specific SLE
sub-phenotypes.12–15 These studies focused mainly on major histocompatibility complex
(MHC) class II genes, and found evidence that class II alleles such as HLA-DRB1*03:01 are
associated with auto-antibody production.13 Our study substantially expands this work by
not only analysing imputed classical human leukocyte antigen (HLA) alleles, but also
examining variant HLA amino-acid positions in conjunction with single-nucleotide
polymorphism (SNP) genotypes across the extended MHC region (chromosome 6: 26–34
Mb). Our aim was to discover genetic loci within the MHC region that are associated with
specific clinical and/or immunological manifestations within SLE cases and hence to find
evidence of genetic variants that may drive specific forms of the disease. For complex
heterogeneous diseases such as SLE, comprehensive sub-phenotype studies are critical in
order to understand how previously identified genetic associations contribute to disease
pathogenesis and specific disease manifestations.

Author Manuscript

RESULTS
Study sample

Author Manuscript

For this study, we collected genetic and sub-phenotype data from 3070 SLE cases of
European descent characterized in four genetic association studies of SLE. These SLE cases
were previously examined in a large meta-analysis that examined the association between
MHC genetic variation and SLE susceptibility.16 Table 1 describes the genotyping platform,
number of genotyped MHC SNPs, and sample size of each case collection in the study.
Given the strong genetic associations observed with anti-Ro/SSA and anti-La/SSB
autoantibody production described below, Table 1 also provides the frequency of these
antibodies for each case collection. Genetic (SNP) imputation was performed previously16
for each case collection, resulting in a total of 7119 SNPs common between the four
collections. In addition, classical HLA class I and II alleles as well as their corresponding
variant amino acids (AAs, see Materials and Methods) were imputed and analysed.
Selection of sub-phenotypes for analysis

Author Manuscript

We examined the 11 ACR classification criteria17 and 7 SLE-related autoantibodies (antidouble-stranded DNA, anti-Sm, anti-RNP, anti-Ro/SSA, anti-La/SSB, anti-cardiolipin IgG
and anti-cardiolipin IgM) as candidate sub-phenotypes for this study. Single-marker
associations for each candidate sub-phenotype with all variants were assessed using logistic
regression adjusted for population substructure and case collection (Supplementary Table 1).
We analysed 7656 variants in total (7119 SNPs, 199 HLA alleles and 338 HLA amino-acid
positions (see methods)). The specific sub-phenotypes comprising anti-Ro and anti-La
antibodies demonstrated by far the most associations: 1635 and 1828 variants, respectively,
at P<0.00001. For all other sub-phenotypes, there were fewer than 30 variants that were
significant at this level. Thus, we targeted anti-Ro and anti-La antibody subsets for detailed
investigation as they have the strongest evidence for a genetic aetiology.
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Stepwise conditional analysis—The most associated marker (in terms of P-value as a
single marker) was the class III SNP rs3129962 in BTNL2 (P =9.47 × 10 −27; odds ratio
(OR) = 2.44, 95% confidence interval (CI) =2.08–2.94; Table 2A). This marker is in linkage
disequilibrium (LD) with HLA-DRB1*03:01 (R2 =0.84, D′ =0.99). When conditioning on
this SNP as a covariate in forward stepwise regression, the next most associated marker was
the class II SNP, rs9271731, between HLA-DRB1 and HLA-DQA1 (P = 9.56 × 10 −07; OR =
1.54, 95% CI =1.30–1.85). This SNP is in LD with HLA-DRB1*15:01 (R2 =0.72, D′ = 1).
When using rs9271731 as an additional covariate, one further association signal was
detected at the class II SNP, rs3957146, between HLA-DQB1 and HLA-DQA2 (P =5.70 ×
10 −06; OR =0.52, 95% CI =0.39–0.69). Of note, the effect sizes (ORs) and P-values that we
present here are estimated from the multivariate models returned by stepwise regression
(columns 2–3 in Table 2). The association results for a given variant from single marker
analyses can be seen in the last two columns of Table 2.

Author Manuscript

The most associated amino acid (AA) was at position 77 in HLA-DRB1 with the common
AA threonine having a protective effect (P =2.72 × 10−13; OR =0.49; 95% CI =0.41–0.60).
HLA-DRB1*03:01 and HLA-DRB1*03:02 encode the single alternative AA, asparagine, (R2
=1). HLA-DRB1*03:02 is not significantly associated with this sub-phenotype (P =0.37)
possibly because of this allele being rare (frequency of 0.01% in our data). We cannot be
certain that this lack of association applies to the general population and this needs to be
investigated to address this uncertainty. All other HLA-DRB1 alleles code for threonine. The
single marker P-value for this AA was very close to that of the most strongly associated
SNP (see last column in Table 2). Therefore, we ran a stepwise regression starting from this
marker. When conditioning on this AA, the next most associated marker was the class II
SNP, rs9271731, between HLA-DRB1 and HLA-DQA1 (P =4.5 × 10−08; OR = 1.63, 95% CI
=1.37–1.95). When using rs9271731 as an additional covariate, one further association
signal was detected at the class III SNP, rs3130781, in DPCR1 (P =1.76 × 10−05; OR =1.44,
95% CI =1.22–1.71). The SNP rs3130781 is in LD with HLA-DRB1*03:01 (R2 = 0.29, D′
=0.64) and HLA-B*08:01 (R2 =0.29, D′ =0.72). One final association signal was detected at
HLA-DQB1*03:02 (P =2.49 × 10−05; OR =0.56, 95% CI = 0.42–0.73). The results from this
analysis can be seen in Table 2B.

Author Manuscript

Owing to the correlation between the most associated SNPs with known associated HLADRB1 alleles (rs3129962 tags HLA-DRB1*03:01/Thr77 in DRB1 (R2 =0.84); rs9271731
tags HLA-DRB1*15:01), we performed stepwise regression conditioning on these HLA
alleles as covariates. When conditioning on HLA-DRB1*03:01 and HLA-DRB1*15:01, the
next most associated marker (rs9275582) was in class II between HLA-DQB1-HLA-DQA2
(P =2.99 × 10−06; OR =0.61; 95% CI =0.5–0.76). The most significant HLA allele was
HLA-DQB1*03:02, which is in LD with rs9275582 (R2 =0.29, D′ =0.80). These two sets of
results can be seen in Tables 2C and 2D. We note that HLA-DQB1*03:02 is in LD (R2 =
0.58) with rs3957146 (the third associated SNP in the first stepwise regression presented in
Table 2).
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A simple stepwise regression analysis including only AA variants indicated associations
with Thr77, Leu67 and Gln96 in HLA-DRB1 (Table 2E). The HLA-DRB1 AA glutamine at
position 96 is in LD with HLA-DRB1*15:01 (R2 =0.82, D′ =1.00).

Author Manuscript

Model choice using the bayesian information criterion (BIC)—Owing to the
extended LD, an analysis of the MHC using stepwise regression to find evidence for
multiple independently associated variants can lead to many models depending on the first
marker conditioned on (used as a covariate for further association analysis). This was
discussed previously16 and here we also used the BIC as an aid to model choice; the lower
the BIC, the better fit the model is to the data (see methods). In our analysis of subphenotype data, there was not much difference between models A, C, D and E in Table 2 in
terms of the BIC, which represents the relative belief in a model given the data. However,
model B, which began the forward stepwise regression with threonine at position 77 in HLADRB1, had the lowest BIC. This model does have one more term than the other four models.
Our extended model search (see methods) did not result in a model with a lower BIC.

Author Manuscript

Haplotype analysis—There are two main extended MHC haplotypes associated with
SLE in northern Europeans that contain the class II alleles HLA-DRB1*03:01 and HLADRB1*15:01.18 These extended haplotypes are comprised of the following HLA alleles:
HLA-A*03:01—HLA-B*07:02—HLA-C*07:02—HLA-DRB1*15:01—HLA-D QA1*01:02
—HLA-DQB1*06:02 and HLA-A*01:01—HLA-B*08:01—HLA-C*07:01—HLADRB1*03:01—HLA-DQA1*05:01—HLA-DQB1*02:01. We tested for association of these
extended haplotypes with anti-Ro antibody status with the hypothesis that the association
signals at HLA-DRB1*03:01 and HLA-DRB1*15:01 are independent of these haplotypes.
We observed significant effects for both haplotypes (HLA-DRB1*03:01: P =1.02 × 10−12,
OR =2.17; HLA-DRB1*15:01: P =0.02, OR =1.71). We found evidence that HLADRB1*03:01 is associated independently of the HLA-B*08:01-DRB1*03:01 haplotypic
background (P = 3.05 × 10−07), whereas we fail to find evidence that HLA-DRB1*15:01 (P
= 0.17) is independent of the HLA-B*07:02-DRB1*15:01 haplotype.
Anti-La antibody subphenotype

Author Manuscript

Stepwise conditional analysis—The most strongly associated marker with the anti-La
autoantibody sub-phenotype was the SNP rs2894254, in the class III region (P =3.40 ×
10−30; OR = 3.38, 95% CI =2.74–4.16). This SNP is in LD (R2 =0.84, D′ = 0.99) with HLADRB1*03:01. We do not find further associations when conditioning on this SNP as a
covariate. However, if we condition on HLA-DRB1*03:01, we find a further association
with rs9268832, located between HLA-DRA and HLA-DRB5 in class II (P =6.53 × 10−06;
OR =1.64; 95% CI =1.32–2.04). Results from these two models can be seen in Table 3. The
HLA-DRB1 AA threonine at position 77 was observed to have a protective effect, consistent
with the anti-Ro analyses. However, this AA was not the most associated marker (P =2.4 ×
10−28). Conditioning on Thr77, we find an additional association with rs2227139, located in
HLA-DRA in class II (P =6.47 × 10−06; OR = 1.64; 95% CI =1.32–2.04). The SNP,
rs2227139, is in LD with rs9268832 (R2 = 0.91, D′ =0.96).
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Model choice using the BIC—As with the analysis of anti-Ro, we used the BIC as an
aid to model comparison. The model including AA variation has the lowest BIC (model C in
Table 3) but is only slightly lower than the model conditioning on HLA-DRB1*03:01.
Therefore, we cannot choose between the AA and the HLA allele as the best explanation for
the data; however, conditional on either of these we find an independent association in class
II. Both of these models have a lower BIC than model A, which only has the single most
associated SNP (rs2894254). These data therefore favour two independent associations in
class II, one of which is most likely HLA-DRB1*03:01 or the HLA-DRB1 AA threonine at
position 77. Our extended model search (see methods) returned the same models as in Table
3.

Author Manuscript

Haplotype analysis—We observed significant effects for the HLA-DRB1*03:01
haplotype but not the HLA-DRB1*15:01 haplotype with anti-La antibody status (HLADRB1*03:01: P =1.19 × 10 −16, OR =3.12; HLA-DRB1*15:01: P =0.63). We found
evidence that HLA-DRB1*03:01 is associated independently of the HLA-B*08:01DRB1*03:01 haplotype (P = 6.42 × 10 −13).
Independence of anti-Ro and anti-La autoantibody associations with HLA-DRB1*03:01
Thus far, we have observed strong evidence of association between HLA-DRB1*03:01 and
both anti-Ro and anti-La autoanti-body subsets. As these two phenotypes are correlated (R2
=0.27), we performed conditional analyses to determine whether the associations for each
sub-phenotype were independent of each other. We performed logistic regression analysis
with each sub-phenotype as an outcome and the other sub-phenotype as a covariate. Table 4
displays the sample sizes and HLA-DRB1*03:01 frequencies for these case only analyses.

Author Manuscript
Author Manuscript

When conditioning on anti-La as a covariate, HLA-DRB1*03:01 continues to be strongly
associated with anti-Ro antibody status (P = 1.23 × 10 −07, OR =1.60 95% CI =1.02–2.54).
Also, when conditioning on anti-Ro, HLA-DRB1*03:01 continues to be strongly associated
with anti-La antibody status (P =1.66 × 10 −12, OR =2.57 95% CI =1.98–3.34). To assess
the robustness of these conditional regression results, we examined the anti-Ro association
in only anti-La-negative cases and found that HLA-DRB1*03:01 was still strongly
associated with anti-Ro (P =6.79 × 10 −07, OR =1.58 95% CI =1.32–1.89). In anti-La
antibody-positive SLE cases, HLA-DRB1*03:01 is weakly associated with anti-Ro (P =
0.055, OR = 2.37 95% CI =0.98–5.74). We performed the same analyses for the anti-La
antibody subset, stratifying on the anti-Ro phenotype. In anti-Ro-positive SLE cases, HLADRB1*03:01 is strongly associated with anti-La (P =6.18 × 10 −12, OR =2.81 95% CI
=2.09–3.77). Among anti-Ro-negative SLE cases, HLA-DRB1*03:01 is weakly associated
with anti-La (P =0.06, OR =1.96 95% CI =0.97–3.73). Therefore, we conclude that the
association signal for HLA-DRB1*03:01 with anti-La is not due to this sub-phenotype’s
correlation with anti-Ro, and vice-versa.
The HLA-DRB1*03:01 association with SLE susceptibility is independent of the association
with anti-Ro and anti-La antibody subsets
We have provided strong evidence for the association between HLA-DRB1*03:01 and both
anti-Ro and anti-La antibody subsets. This HLA-DRB1 allele has been consistently and
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strongly associated with SLE susceptibility in European populations,16 and this is confirmed
in our current data (P =3.38 × 10−49; OR =1.86 95% CI =1.71–2.02). However, the
association of HLA-DRB1*03:01 with anti-Ro/anti-La antibody subsets and SLE
susceptibility may not be independent—the DRB1*03:01 association with SLE may be
purely secondary to its association with anti-Ro and anti-La antibody status.

Author Manuscript

If the association between HLA-DRB1*03:01 and SLE status is not driven entirely by subphenotype then one could hypothesize a three-level model of disease type (unaffected; subphenotype-negative case; sub-phenotype-positive case) based on increasing HLADRB1*03:01 frequency. Figure 1 plots the change in HLA-DRB1*03:01 dosage over levels
of disease; the average dosage appears to increase over all three levels. Therefore, we
examined (see methods) the hypothesis that the HLA-DRB1*03:01 association with anti-Ro
and anti-La antibody sub-phenotypes explains the association of DRB1*03:01 with SLE in
general. We also tested whether the risk was additive over the three levels of disease.
Anti-Ro antibody sub-phenotype
We found a significant difference in HLA-DRB1*03:01 dosage between healthy controls and
anti-Ro antibody negative cases (P = 1.97 × 10 −14). The estimated change in dosage was
0.1 (95% CI =0.08–0.13), equivalent to a change in allele frequency of 0.05 (95% CI =0.04–
0.06).
We also found a significant increase in dosage between anti-Ro-negative cases and anti-Ro
positive cases (P =2.97 × 10−33). The estimated change in dosage (see Table 5) is 0.27 (95%
CI =0.22–0.31), equivalent to a change in frequency of 0.13 (95% CI = 0.11–0.16).

Author Manuscript

We found evidence against the hypothesis that the increase in dosage is additive over the
three disease levels (P =0.008). Our final test against the additive model implies that the
difference in HLA-DRB1*03:01 dosage between anti-Ro(−)/anti-Ro( +) status (increase of
0.27) in the cases is more than double that of the difference between cases and healthy
controls (increase of 0.10).
Anti-La antibody subphenotype
We found a significant difference in HLA-DRB1*03:01 dosage between healthy controls and
anti-La-negative cases (P =3.57 × 10 −25). The estimated change (see Table 5) in dosage is
0.13 (95% CI = 0.11–0.15), equivalent to a change in frequency of 0.06 (95% CI =0.05–
0.08).

Author Manuscript

We also found a significant increase in dosage between anti-La-negative and anti-Lapositive cases (P = 2.45 × 10 −39). The estimated change in dosage (see Table 5) is 0.41
(95% CI =0.35–0.47), equivalent to a change in frequency of 0.21 (95% CI =0.18–0.24).
We found evidence against the hypothesis that the increase in dosage is additive over the
three disease levels (P =1.5 × 10 −04). Table 5 displays the effect sizes and P-values for this
analysis. Our final test against the additive model implies that the difference in HLADRB1*03:01 dosage between anti-La( −)/anti-La( + ) status (increase of 0.41) in the cases is
more than triple that of the difference between cases and healthy controls (increase of 0.13).
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Our study was large enough to determine whether the frequency of HLA-DRB1*03:01
differs between SLE cases who are double negative for anti-Ro and anti-La antibodies (N
=1781) and healthy controls (N =9782). It is known that these antibodies are present in
approximately 2% of the healthy population; however, we do not have this phenotype data
for the controls. The following results therefore assume that all controls are negative for
antinuclear antibodies. We found a significant association of HLA-DRB1*03:01 with the
double negative SLE cases/healthy controls status (OR =1.49, 95% CI =1.35–1.65; P = 2.23
× 10 −14). Further analysis demonstrated a stronger association with the double positive (n
=259)/double negative SLE case status (OR =3.71, 95% CI = 2.97–4.64; P =2.00 × 10 −16).
To test whether these two odds ratios differ, we ran the same analysis for a three-stage risk
model as we did for anti-Ro and anti-La antibody subsets separately (see above, Table 5
results). We found very strong evidence against the hypothesis that the increase in dosage is
additive over the three disease levels (P = 6.65 × 10 −06). The non-additive effect leads to a
very large odds ratio between double positive SLE cases and healthy controls, which we
found to be 5.27 (95% CI = 4.31–6.44; P =3.14 × 10 −59; Figure 1).

DISCUSSION

Author Manuscript

Our results confirm, in the largest SLE sub-phenotype genetic association study to date, that
the often replicated genetic association at HLA-DRB1*03:01 does not just influence SLE
susceptibility but is also associated with anti-Ro and anti-La autoantibody production. For
the first time, we have shown that HLA-DRB1*03:01 is associated with SLE per se,
independent of anti-Ro and anti-La antibody subsets. These data implicate HLADRB1*03:01 and variants in LD with it in the predisposition to anti-Ro and anti-La
autoantibody production as well as processes outside of this manifestation.

Author Manuscript

We do not find conclusive evidence that variant HLA AAs explain the majority of the MHC
association signal in anti-Ro and anti-La autoantibody subsets in SLE. This is largely due to
the confounding effects of extended LD displayed by the associated DRB1*03:01 and to a
lesser extent, the DRB1*15:01 haplotypes in our study cohorts. These results contrast with
those of a recent study in anti-CCP-positive rheumatoid arthritis, where five HLA AA
variants were suggested to largely explain the MHC association with disease status.19 In this
case, the disease-associated variants generally reside on a diversity of haplotypes. Studies in
other autoimmune/inflammatory diseases have either not shown robust association signals
with variant HLA AA data or like the present study have shown association with AAs in
strong LD with previously associated HLA alleles. It may be that HLA amino association
signals are more complex than the single-variant testing method we and others have used.
Limitations of the present study include the heterogeneity in autoantibody testing procedures
and sub-phenotype data collection between the four studies. As a result, data were tabulated
and analysed in an essentially binary format (that is, individual cases were classified as
positive, negative or missing for each trait), to allow meta-analysis. However, in so doing, a
degree of noise is inevitable, which would reduce our power to detect true association
signals particularly in the less common sub-phenotypes. We were also limited by the
imputation required to analyse a consistent set of SNPs across studies and the reliance on
Genes Immun. Author manuscript; available in PMC 2014 July 18.
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HLA imputation. In addition, we are constrained in our conclusions on differences in results
for anti-Ro and anti-La antibody subsets given the much smaller sample size available for
the anti-La phenotype. Thus, we have confined some of our analyses to the most robust
association; that of HLA-DRB1*03:01 with both anti-Ro and anti-La antibody subphenotypes. We must also allow for the possibility that associations with HLA-DRB1*03:01
could exist with other SLE subsets that overlap with anti-Ro/La, but have not been detected
in our study. This highlights the need for extension of this work to other cohorts with subphenotype data in order to increase sample size and power across as wide a range of
phenotypes as possible.

Author Manuscript

In both anti-Ro and anti-La sub-phenotypes, we find evidence of secondary independent
associations in the class II region of the MHC after conditioning on HLA-DRB1*03:01, and
we find additional signals in class II and class III for anti-Ro. We have shown that the
association of HLA-DRB1*03:01 with anti-Ro antibody status is independent of the
association with anti-La and vice-versa. We have also shown that the association between
SLE case/healthy control and HLA-DRB1*03:01 is not purely due to the association with
anti-Ro and anti-La antibody sub-phenotypes. This implies a three-level model of risk for
increasing dosage of HLA-DRB1*03:01, where the frequency of this allele is higher in antiRo-negative cases than in healthy controls and higher still in anti-Ro-positive cases than
anti-Ro-negative cases. The same is true for anti-La. In fact, we find very strong evidence
that the HLA-DRB1*03:01 risk of anti-Ro/anti-La double positive within SLE patients is
much greater than the risk of anti-Ro/anti-La double negative (other lupus phenotypes
without these anti-bodies present) in the general population. We can conclude that the
association of HLA-DRB1*03:01 with SLE is driven to a large extent but not entirely by
anti-Ro and anti-La auto-antibody sub-phenotypes.

Author Manuscript
Author Manuscript

Although we do find evidence of an independent class III association with anti-Ro, there is
some uncertainty. We find a significant association with the class III SNP rs3130781
conditional on the AA Thr77-DRB1. However, when conditioning on the markers in model
C in Table 2 (HLA-DRB1*03:01 +HLA-DRB1*15:01 + rs9275582; BIC =2829.8) in a
forward stepwise regression, the association with rs3130781 is not significant (P = 4.2 ×
10 −05). This is also the case for model D in Table 2 (HLA-DRB1*03:01 + HLADRB1*15:01 +HLA-DQB*03:02; BIC =2829.6). So conditional on HLA-DRB1*03:01 and
HLA-DRB1*15:01, we find an independent association in class II but not class III. However,
we did consider conditioning on HLA-DRB1*03:01 alone, where a stepwise regression
returned a class II SNP (rs9271731; R2 with HLA-DRB1*15:01 =0.72) and the class III SNP
rs3130781. This model has a BIC =2929.00. Hence, there is uncertainty as to whether there
is an independent class III effect when conditioning on HLA-DRB1*03:01; all three models
fit the data equally well (not much difference in the BIC). Nevertheless, the best model in
Table 2 does suggest that there is an independent class III effect conditional on the class II
AA Thr77-DRB1. This model has a much lower BIC than any others. There is some
evidence, therefore, of a class III association with anti-Ro; however, we believe that more
data, and ideally across diverse populations (to help remove effects due to LD), are required
to be more definitive about this.
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The results of the present study while enlightening are confounded by the strong and
extended LD present on the principally associated HLA-DRB1*03:01 and HLA-DRB1*15:01
haplotypes. Complementary studies in accurately phenotyped southern European and nonEuropean SLE cohorts, which show haplotypic diversity at the MHC, will allow refinement
of the sub-phenotype association signals found in the predominantly northern European
populations studied thus far.20 These efforts may still yield association intervals that harbour
several genes/variants. Therefore, future work will inevitably require re-sequencing,
transcriptomic and epigenetic studies in order to tease out these complex association signals.

MATERIALS AND METHODS
Study design

Author Manuscript

This study is a meta-analysis of four studies taken from work described in a previous
paper.16 We only included four of the six previous studies in this work as sub-phenotype
data were not available from the other two studies (named ‘Affy500K’ and ‘Affy100K’ in
the previous paper). We refer to the previous meta-analysis of SLE case–control data as the
‘parent study’ in this work. The number of SLE cases and controls in this paper for the four
included studies are the same as in the parent study, and quality control (QC) procedures for
these data are described in full in the previous paper, including tests for relatedness and
adjustments for population structure. We include some QC descriptions below for clarity in
this paper.
QC and imputation

Author Manuscript

SNPs—We only analysed SNPs that passed QC in our previous paper,16 which utilized
these data: 90% genotyping for all subjects and SNPs, minor allele frequency >0.01 and
Hardy–Weinberg equilibrium (false discovery rate of 0.05).

Author Manuscript

HLA imputation—We imputed HLA genotypes using HLA*IMP V2.21 Only genotyped
SNPs in each case collection were used for this imputation. We used posterior probabilities
of HLA genotypes, rather than most likely genotypes, in order to allow for uncertainty in
imputation. From these probabilities, we calculated dosages for each allele (expected
number of alleles 0<x<2). We had HLA-DRB1 typed data in two studies: the ‘Illumina
Combined MHC panel’ study (N =1608) and the ‘Illumina Custom panel’ study (N = 605).
This allowed for assessment of accuracy, which for the two main reported positive
associations in this paper were as follows: for HLA-DRB1*03:01, we achieved sensitivity of
0.992/0.999 and specificity of 0.995/0.993 for the Illumina Combined MHC panel and
Illumina Custom panel’ respectively. For HLA-DRB1*15:01, we achieved sensitivity of
0.980/0.992 and specificity of 0.996/0.997.
AA translation
AA sequences for each HLA allele were extracted from the European Bioinformatics
Institute HLA database (http://www.ebi.ac.uk/ipd/imgt/hla/). HLA allele dosages were
converted to AA dosages at each position; the dosage for a particular amino acid ‘A’ at
position ‘p’ would be the sum of HLA alleles’ dosage that coded for amino acid ‘A’ at
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position ‘p’. The total dosage for each position is therefore equal to 2 and this total is split
between each possible AA at the position.
We had data at 338 AA positions that had variable AAs (HLA-A =67, HLA-B = 75, HLA-C
=71, HLA-DPB1 = 21, HLA-DQA1 = 41, HLA-DQB1 =61, HLA-DRB1 = 52). Owing to
multiple possible AAs at each position, we actually had 1255 possible position/AA variants
in total.

Author Manuscript

Adjustment for population structure—We analysed the data with the statistical
computing language R22 using logistic regression. All analyses were adjusted for ancestry
utilizing the first principal component (PC) or percentage of northern European ancestry, as
previously described16 and included a covariate for project. As the PCs were computed
specifically for each case collection, we also included interaction terms between projects and
ancestry to allow for different effect sizes in the adjustment for population structure.

Author Manuscript

Single-marker analysis of candidate sub-phenotypes and analysis of SLE as a
simple disease outcome—We examined the 11 ACR criteria17 and presence of 7 SLErelated auto-antibodies (anti-Ro/SSA, anti-La/SSB, anti-double-stranded DNA, anti-RNP,
anti-Sm and anticardiolipin IgG and IgM) as candidate sub-phenotypes for detailed analysis.
To determine which sub-phenotypes were most strongly influenced by genetic variation in
the MHC, we tested each sub-phenotype for association with all variants (SNPs, HLA alleles
and HLA AAs) in single-variant association tests using logistic regression adjusted for
population substructure and case collection. We also tested the association between markers
and SLE as a simple disease outcome for the four studies considered here. Results for
association with HLA-DRB1*03:01 are discussed in the beginning of the section titled ‘The
HLA-DRB1*03:01 association with SLE susceptibility is independent of the association with
anti-Ro and anti-La antibody subsets’.
Conditional association analysis of anti-Ro and anti-La—Owing to numerous
single-marker associations within the extended LD of the MHC, we used conditional
analyses to narrow these associations to those with the best evidence for strength and
independence. All analyses utilized logistic regression with ancestry and project covariates
(see above) and were halted when the evidence for association with a new term was P>3 ×
10 −05. We performed classic forward stepwise regression, conditioning on the top variant to
find the second variant, and so on.

Author Manuscript

A simple forward stepwise approach can lead to over-fitting (selecting many correlated
markers) and the results may be misleading because of selected markers potentially tagging
two or more independently associated markers.16 Therefore, we also performed a model
search using the BIC16 as the inclusion metric in a stepwise regression using the R22 ‘step()’
function, first starting with no prior model (other than covariates above) and also starting
from HLA-DRB1*03:01 and HLA-DRB1*15:01 as initial model terms. Although BIC
optimization was used to select model terms, we terminated the selection when it would
result in a term with P>3 × 10−5. The BIC23,24 is a penalized likelihood model choice
criterion similar to the Akaike Information Criterion24 except there is a stronger penalty for
additional model parameters that increases with sample size. The BIC is therefore more
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conservative and favours smaller models than the Akaike Information Criterion. As with the
Akaike Information Criterion, the smaller the BIC the better the model is judged to fit the
data.
Haplotype analysis of anti-Ro and anti-La—Given the high degree of correlation
between the associated variants identified from the model searches described above, we
conducted a haplotype analysis of these variants using PLINK25 using the best-guess
genotypes estimated from HLA*IMP2. We used PLINK to phase haplotypes and perform
multivariate logistic regression where terms are haplotypes rather than individual variants,
optionally controlling for individual variants or haplotypes.

Author Manuscript

Multiple testing—In the MHC, a Bonferroni adjustment for multiple testing is
inappropriate because of the extensive LD and hence correlated variants. In order to
determine the number of independent variants, we performed a PC analysis of all SNPs. In
our data, we found that 374 PCs had eigenvalues >1 and these PCs explained 96% of the
variance. Thus, we used a multiple-testing threshold of P<0.01/374 = 3 × 10 −5.

Author Manuscript

Testing for independence between the SLE association and sub-phenotype
association with HLA-DRB1*03:01—We fitted a linear regression model with dosage
for HLA-DRB1*03:01 as the outcome and both case/control status and sub-phenotype status
as explanatory variables. We therefore tested each effect conditional on the other. A
significant association for case/control status conditional on sub-phenotype implies that we
reject the hypothesis that sub-phenotype is solely driving the case/control association. This
is equivalent to setting the three-level status as a factor in the regression in terms of model
fit. But rather than obtaining an estimate of dosage change between healthy controls and
sub-phenotype positive as we would in a three-level factor (where the baseline is healthy
control), we get an estimate of change between sub-phenotype positive and sub-phenotype
negative. In both models, we also get an estimate of change between healthy controls and
sub-phenotype negative.

Author Manuscript

Furthermore, we tested the hypothesis that the increase in dosage is additive over the three
disease levels (Healthy-Control Case sub-phenotype negative/Case sub-phenotype positive).
This is achieved by fitting a model with an additive effect for dosage over the three
phenotype levels. This additive model is nested within our model used to test independence
of sub-phenotype association with SLE-case/healthy control, so we performed a likelihood
ratio test. A rejection of this additive model, in favour of the three-level factor model
(described in the previous paragraph), is evidence that the change in dosage over subphenotype within cases is different than the change in dosage between healthy controls and
SLE without the sub-phenotype.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Author Manuscript

HLA-DRB1*03:01 dosage (average number of alleles observed) over levels of disease (a):
(healthy controls/anti-Ro( −)/anti-Ro( +)); (b): (healthy controls/anti-La( −)/anti-La( +)); (c)
(healthy controls/anti-Ro( −) AND anti-La( −)/anti-Ro( +) AND anti-La( +)/). Average
dosage is represented by a square, whereas upper and lower 95% confidence intervals are
represented by ‘ −’. Note that dosage ranges from 0 to 2 for each subject and so to convert to
allele frequency you must divide by 2. All three plots have been truncated at 1.
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Individual studies with number of genotyped SNPs, number of SLE cases and sample sizes for anti-Ro/La
within cases
N genotyped MHC SNPsa

Study case collection

N casesb

Sample sizes (+/−/missing)

HumanHap5506

2380

1123

Anti-Ro: 319/796/8
anti-La: 137/978/8

Illumina HumanHap3175

1522

398

Anti-Ro: 36/107/225
anti-La: 17/126/255

Illumina Combined MHC panel26

2360

917

Anti-Ro:158/454/305
anti-La:79/531/307

Illumina custom panel27

1230

632

Anti-Ro: 168/446/18
anti-La: 48/565/19

Illumina

Abbreviations: MHC, major histocompatibility complex; SLE, systemic lupus erythematosus; SNP, single-nucleotide polymorphism. The last
column denotes the number of SLE cases who were positive, negative or had missing data for each sub-phenotype.
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a

Number of SNPs on the genotyping platform located on chromosome 6 between 26 000 and 34 000 kb.

b

See original paper16 for a description of SLE case recruitment.
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OR (95% CI)

P-value

5.70 × 10−06
Class II

Class II

10−07

9.56 ×

Class III

9.47 × 10−27

DQB1-DQA2

DRB1-DQA1

BTNL2

Gene

1.63 (1.37–1.95)
1.44 (1.22–1.71)
0.56 (0.42–0.73)

rs9271731 (A<G)

rs3130781 (G<A)

HLA-DQB1*03:02

Class II
Class III
Class II

4.50 × 10−08
1.76 × 10−05
10−05

2.49 ×

Class II

2.72 × 10−13

DQA1

DPCR1

DRB1-DQA1

DRB1

0.42 (0.33–0.55)

1.95 (1.69–2..25)

1.27 (1.09–1.49)

0.45 (0.39–0.52)

0.38 (0.29–0.50)

1.27 (1.09–1.49)

2.32 (1.98–2.71)

OR (95% CI)

1.54 (1.28–1.85)
0.61 (0.50–0.75)

HLA-DRB1*15:01

rs9275582 (A<G)

Class II
Class II

10−06

2.99 × 10−06

4.11 ×

Class II

1.11 × 10−20

DQB1-DQA2

DRB1

DRB1

1.63 (1.36–1.95)
0.53 (0.41–0.70)

HLA-DRB1*15:01

HLA-DQB1*03:02

Class II
Class II
Class II

1.21 × 10−25
9.71 × 10−08
4.84 × 10−06
DQB1

DRB1

DRB1
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0.64 (0.53–0.77)
1.47 (1.23–1.76)

Leu67 DRB1

Gln96 DRB1

Class II
Class II

10−06

2.29 × 10−05

2.81 ×

Class II

4.00 × 10−32

DRB1

DRB1

DRB1

1.29 (1.11–1.51)

1.05 (0.93–1.20)

0.45 (0.39–0.52)

0.42 (0.33–0.55)

1.32 (1.13–1.57)

2.22 (1.91–2.59)

0.45 (0.38–0.55)

1.32 (1.13–1.57)

2.22 (1.91–2.59)

1.28 × 10 −03

4.22 × 10 −01

5.26 × 10 −25

1.67 × 10 −10

7.42 × 10 −04

9.29 × 10 −25

6.12 × 10 −16

7.42 × 10 −04

9.29 × 10 −25

Abbreviations: BIC, bayesian information criterion; CI, confidence interval; HLA, human leukocyte antigen; OR, odds ratio; SNP, single-nucleotide polymorphism. SNPs have their minor and major alleles
noted in brackets (A<G where A is the minor allele, for example), the OR is with respect to the minor allele. For BIC see Materials and Methods.

0.29 (0.24–0.36)

Thr77 DRB1

(E)Forward stepwise regression analysing amino acid data only (BIC =2827.2)

2.38 (2.02–2.80)

HLA-DRB1*03:01

(D) Forward stepwise regression analysing HLA alleles only (BIC =2829.6)

2.22 (1.88–2.66)

HLA-DRB1*03:01

1.67 × 10 −10

2.19 × 10 −20

2.58 × 10 −03

5.26 × 10 −25

3.10 × 10 −12

2.58 × 10 −03

2.02 × 10 −25

P-value

Single marker

(C) Forward stepwise regression conditioning on HLA-DRB1*03:01 + HLA-DRB1*15:01 (BIC = 2829.8)

0.49 (0.41–0.60)

Thr77 DRB1

(B) Forward stepwise regression beginning from Thr77 DRB1 (BIC =2815.9)

0.52 (0.39–0.69)

1.54 (1.30–1.85)

rs9271731 (A<G)

rs3957146 (G<A)

2.44 (2.08–2.94)

rs3129962 (A<G)

Class

Estimates from the multiple regression model

(A) Forward stepwise regression (BIC = 2826.1)

Marker
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Table 2
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Author Manuscript

Author Manuscript
OR

95% CI

P-value

3.38

2.74–4.16

3.40 × 10−30
Class III

1.64

rs9268832 (C<A)

1.32–2.04

2.00–3.13

HLA-DRB1
DRA-DRB5

1.40 × 10−15
6.53 × 10−06
Class II

1.64

rs2227139 (C<A)

1.32–2.04

0.32–0.50
HLA-DRA

Class II

10−06

6.47 ×

HLA-DRB1

1.33 × 10−15
2.32

0.32

2.31

3.15

3.38

OR

1.86 × 10 −17

2.40 × 10 −28

2.46 × 10 −17

3.31 × 10 −28

3.40 × 10 −30

P-value

Single marker

Abbreviations: BIC, bayesian information criterion; CI, confidence interval; OR, odds ratio. SNPs have their minor and major alleles noted in brackets (A<G where A is the minor allele, for example), the
OR is with respect to the minor allele. For BIC see Materials and Methods.

0.40

Thr77 DRB1

Gene

c6orf10—BTNL2

(C) Forward stepwise regression starting from AA-DRB1*77T (BIC =1672.53)

2.50

HLA-DRB1*03:01

(B) Conditional on HLA-DRB1*03:01 as a covariate (BIC = 1673.31)

rs2894254 (C<A)

Class

Estimates from the multiple regression model

(A) Forward stepwise regression (BIC = 1677.92)

Marker

Author Manuscript

Forward stepwise regression models for anti-La

Author Manuscript
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Table 4

Author Manuscript

Allele frequencies for HLA-DRB1*03:01 in case only association analysis of anti-Ro and anti-LA when
conditioning on the status of each sub-phenotype
Status

Anti-La( +), N

Anti-La( −), N

Anti-Ro( +)

0.41 (259)

0.26 (418)

Anti-Ro( −)

0.28 (22)

0.18 (1781)

Frequencies for the HLA-DRB1*03:01 allele are shown with the sample sizes in brackets.

Author Manuscript
Author Manuscript
Author Manuscript
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Table 5

Author Manuscript

Multi-level model for HLA-DRB1*03:01 dosage over phenotype
Phenotype

Effect (change in dosage)

95% CI

P-value

Anti-Ro( −)/control

0.10

0.08–0.13

1.97 × 10 −14

Anti-Ro( +)/anti-Ro(−)

0.27

0.22–0.31

2.97 × 10 −33

Anti-La( −)/control

0.13

0.11–0.15

3.57 × 10 −25

Anti-La( +)/anti-La( −)

0.41

0.35–0.47

2.45 × 10 −39

(A) Results for anti-Ro

(B) Results for anti-La

Abbreviation: CI, confidence interval. Effect is the change in dosage for HLA-DRB1*03:01 between positive and negative for specified phenotype.
(A) Results for healthy control/anti-Ro-negative/anti-Ro-positive. (B) Results healthy control/anti-La-negative/anti-La-positive.
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